Seminari "Extending PARPi targeting HR defects into early breast cancer through OlympiA and understanding and tackling clinical resistance when PARPi fail" Dr. Andrew Tutt

Speaker: Andrew Tutt, Head of the Division of Breast Cancer Research and Director of the Breast Cancer Now Toby Robins Research Centre at the ICR, London Talk 

Host: Violeta Serra / Judith Balmaña

Professor Tutt has developed a translational laboratory for triple negative breast cancer. He leads a clinical trial programme focusing on TNBC and cancers associated with functional deficiencies in BRCA1 and BRCA2.

He also leads translational laboratories at both the ICR and KCL, studying BRCA1 and BRCA2 associated TNBC forms of breast cancer. Andrew’s group publishes in high impact journals regularly and amongst their latest work they published a new TNBC target, PIM1 kinase, in Nature Medicine in November 2016.

He is Chief Investigator for the recently reported multicentre UKCRN ”Triple Negative Trial” and is Global Study Chair of the ‘OlympiA’ study – an adjuvant PARP inhibitor trial in patients with germline BRCA 1/2 mutations and breast cancer.

He has been a Visiting Professor at British Columbia Cancer Agency, Jean Lubrano Visiting Scholar at Harvard Medical School, and is a member of the St Gallen Early Breast Cancer International Consensus Panel and recently received the Addarii Award for his work in the field of breast and ovarian cancer research.

Inscriu-t'hi